SAN DIEGO, November 2, 2021 – Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer. This double blind, placebo-controlled Phase 1 study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics … Continue reading Primmune Therapeutics Provides Update on Phase 1 Healthy Volunteer Study of PRTX007, A First in Class Novel Oral TherAjuvant™
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed